Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hallvard Holdaas

Showing results (21-30 of 156) with videos related to

Pageof 16
Sort By:
Transplantation Reviews (Orlando, Fla.)|September 18, 2014
mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?Hallvard Holdaas, Luciano Potena, Faouzi Saliba
Expert Opinion on Drug Safety|September 8, 2012
A drug safety evaluation of everolimus in kidney transplantationHallvard Holdaas, Karsten Midtvedt, Anders Åsberg
Clinical Biochemistry|February 18, 2014
Kidney donors and kidney transplants have abnormal aminothiol redox status, and are at increased risk of oxidative stress and reduced redox buffer capacityTerje Apeland, Hallvard Holdaas, Mohammad A Mansoor
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 13, 2005
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trialHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Journal of Transplantation|November 4, 2016
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateHallvard Holdaas, Paolo De Simone, Andreas Zuckermann
Kidney International|October 24, 2018
Long-term renal allograft survival: a quiet revolutionAlan G Jardine, Anders Hartmann, Hallvard Holdaas
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 25, 2017
Belatacept: Where the BENEFITS Outweigh the RiskHallvard Holdaas, Geir Mjøen, Alan G Jardine
Transplantation|September 7, 2018
Pulse Pressure: A Risk Factor for Renal Transplant Failure or a Useful Therapeutic Target?Matthew Tunbridge, Hallvard Holdaas, Alan G Jardine
Transplant International : Official Journal of the European Society for Organ Transplantation|February 22, 2011
Spontaneous regression of initially elevated peak systolic velocity in renal transplant arteryKnut Brabrand, Hallvard Holdaas, Anne Gunther, et al.
Current Opinion in Organ Transplantation|July 14, 2012
Prevention of cardiovascular disease after renal transplantationMy Svensson, Alan Jardine, Bengt Fellström, et al.
Pageof 16

Showing results (21-30 of 156) with videos related to

Sort By:
Pageof 16
Transplantation Reviews (Orlando, Fla.)|September 18, 2014
mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?Hallvard Holdaas, Luciano Potena, Faouzi Saliba
Expert Opinion on Drug Safety|September 8, 2012
A drug safety evaluation of everolimus in kidney transplantationHallvard Holdaas, Karsten Midtvedt, Anders Åsberg
Clinical Biochemistry|February 18, 2014
Kidney donors and kidney transplants have abnormal aminothiol redox status, and are at increased risk of oxidative stress and reduced redox buffer capacityTerje Apeland, Hallvard Holdaas, Mohammad A Mansoor
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 13, 2005
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trialHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Journal of Transplantation|November 4, 2016
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateHallvard Holdaas, Paolo De Simone, Andreas Zuckermann
Kidney International|October 24, 2018
Long-term renal allograft survival: a quiet revolutionAlan G Jardine, Anders Hartmann, Hallvard Holdaas
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 25, 2017
Belatacept: Where the BENEFITS Outweigh the RiskHallvard Holdaas, Geir Mjøen, Alan G Jardine
Transplantation|September 7, 2018
Pulse Pressure: A Risk Factor for Renal Transplant Failure or a Useful Therapeutic Target?Matthew Tunbridge, Hallvard Holdaas, Alan G Jardine
Transplant International : Official Journal of the European Society for Organ Transplantation|February 22, 2011
Spontaneous regression of initially elevated peak systolic velocity in renal transplant arteryKnut Brabrand, Hallvard Holdaas, Anne Gunther, et al.
Current Opinion in Organ Transplantation|July 14, 2012
Prevention of cardiovascular disease after renal transplantationMy Svensson, Alan Jardine, Bengt Fellström, et al.
Pageof 16